Relay Therapeutics (NASDAQ:RLAY) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below ...

JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of $24.00. Silvan Tuerkcan’s Buy rating for Relay ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on RLAY stock, giving a Buy rating on July 2. Robert Burns has given his Buy rating due to a combination of factors including ...

Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with ...

Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the Top 10 Stocks Under $10 That Could Triple. On September 4, Guggenheim began coverage of Relay Therapeutics, Inc. (NASDAQ:RLAY) with a Buy rating ...

Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the top strong buy stocks under $5 to buy now. Leerink Partners analyst Andrew Berens reiterated a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) ...

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports.